{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:55:46Z","timestamp":1794052546205,"version":"4.8.0"},"reference-count":68,"publisher":"Academy of Medicine, Singapore","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Acad Med Singap"],"published-print":{"date-parts":[[2024,9,27]]},"abstract":"<jats:p>Introduction: Psoriasis is a multisystem, chronic, inflammatory dermatological disease. In routine clinical practice, the management of psoriasis varies significantly. The current study aimed to develop a set of practice guidelines relevant to dermatology practice in Singapore.\n\nMethod: The Psoriasis Therapeutic Guidelines Workgroup, comprising members of the Dermatological Society of Singapore with a subspecialisation in psoriasis, was convened to develop the guidelines. Clinical questions on selected topics were generated and refined by the workgroup. A literature search using PubMed was performed on their assigned topics from June 2013 to December 2023. The articles were included and graded based on the level of evidence.\n\nResults: The guidelines address topics ranging from clinical assessment to practical considerations in the management of mild, moderate and severe psoriasis, including delivery of care, referrals to specialists and adherence to treatment. The recommended therapies include phototherapy, methotrexate, acitretin, cyclosporine; apremilast; topical corticosteroids, calcipotriol, topical calcineurin inhibitors; and biologics (i.e. adalimumab, infliximab, secukinumab, ixekizumab, ustekinumab, etanercept) either in combination or as monotherapy. Common therapeutic concerns relating to biologic use were addressed. Recommendations on generalised pustular psoriasis, palmoplantar pustular psoriasis and psoriatic arthritis were also made. Patients on systemic therapy would receive appropriate vaccine counselling. Therapeutic implications in special populations, such as pregnant\/lactating women, children, the elderly, those undergoing surgery and those suffering from specific infections and cancer were addressed.\n\nConclusion: These guidelines were developed for dermatologists, family physicians, rheumatologists and other specialists to support their selection of appropriate management options.<\/jats:p>","DOI":"10.47102\/annals-acadmedsg.2023367","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T02:37:29Z","timestamp":1727404649000},"page":"562-577","source":"Crossref","is-referenced-by-count":15,"title":["2023 guidelines on the management of psoriasis by the Dermatological Society of Singapore"],"prefix":"10.47102","volume":"53","author":[{"given":"Hazel H","family":"Oon","sequence":"first","affiliation":[{"name":"National Skin Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Tan","sequence":"additional","affiliation":[{"name":"National University Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick Chen Wee","family":"Aw","sequence":"additional","affiliation":[{"name":"Sengkang General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Sheng","family":"Chong","sequence":"additional","affiliation":[{"name":"National Skin Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Yi","family":"Koh","sequence":"additional","affiliation":[{"name":"TSN Dermatology Skin Specialist Clinic, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Leung","sequence":"additional","affiliation":[{"name":"Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar Seng","family":"Lim","sequence":"additional","affiliation":[{"name":"The Dermatology Practice, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiun Yit","family":"Pan","sequence":"additional","affiliation":[{"name":"National Skin Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene Sern-Ting","family":"Tan","sequence":"additional","affiliation":[{"name":"National Skin Centre, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Wei","family":"Tan","sequence":"additional","affiliation":[{"name":"Changi General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Nee","family":"Tham","sequence":"additional","affiliation":[{"name":"TSN Dermatology Skin Specialist Clinic, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Theng","sequence":"additional","affiliation":[{"name":"The Skin Specialists & Laser Clinic, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Ni","family":"Wong","sequence":"additional","affiliation":[{"name":"Dr SN Wong Skin, Hair, Nails & Laser Specialist Clinic, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26165","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"ref0","unstructured":"World Health Organization. Global report on psoriasis, 2016. https:\/\/iris.who.int\/handle\/10665\/204417. Accessed 19 April 2024."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022;18:465-79.","DOI":"10.1177\/2475530321991272"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023: a pragmatic update. Br J Dermatol 2024;190:270-2.","DOI":"10.1093\/bjd\/ljad347"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Morita A, Tsai T-F, Yee EYW, et al. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled EffisayilTM 1 study. J Dermatol 2023;50:183-94.","DOI":"10.1111\/1346-8138.16609"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Agency for Care Effectiveness. Interleukin inhibitors for treating chronic plaque psoriasis and active psoriatic arthritis, 18 January 2021. Updated on 31 August 2022. https:\/\/www.ace-hta.gov.sg\/docs\/default-source\/drug-guidances\/interleukin-inhibitors-for-treating-chronic-plaque-psoriasis-and-active-psoriatic-arthritis-pes-(updated-31-aug-22).pdf. Accessed 22 April 2024.","DOI":"10.1177\/247553031700200402"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Torres T, Chiricozzi A, Puig L, et al. Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study. Am J Clin Dermatol 2024;25:333-42.","DOI":"10.1007\/s40257-024-00845-4"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Wang X, Zhang M, Chen Y, et al. Risk for Hepatitis B Virus Reactivation in Patients with Psoriasis Treated with Biological Agents: A Systematic Review and Meta-Analysis. Dermatol Ther (Heidelb) 2022;12:655-70.","DOI":"10.1007\/s13555-022-00682-5"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"De Brandt E, Hillary T. Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management. Psoriasis (Auckl) 2022;12:113-26.","DOI":"10.2147\/ptt.s293107"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Hebert AA, Browning J, Kwong PC, et al. Managing pediatric psoriasis: update on treatments and challenges\u2014a review. J Dermatolog Treat 2022;33:2433-42.","DOI":"10.1080\/09546634.2022.2059051"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Lambert JLW, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA\u2010PSO: Belgian Evidence\u2010based Treatment Advice in Psoriasis; part 2). J Eur Acad Dermatol Venereol 2020;34:1914-23.","DOI":"10.1111\/jdv.16683"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Orlando G, Molon B, Viola A, et al. Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk? Front Immunol 2022;13:868277.","DOI":"10.3389\/fimmu.2022.868277"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Narbutt J, Nied\u017awied\u017a M, Lesiak A, et al. Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability. Patient Prefer Adherence 2023;17:421-31.","DOI":"10.2147\/ppa.s350753"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Chiu H-Y, Chiu Y-M, Chang Liao N-F, et al. Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study. J Am Acad Dermatol 2021;85:337-44.","DOI":"10.1016\/j.jaad.2019.12.001"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment, 25 February 2020. https:\/\/www.who.int\/publications-detail-redirect\/9789240001503. Accessed 19 April 2024.","DOI":"10.30978\/tb2021-2-86"},{"key":"ref14","unstructured":"Ministry of Health, Singapore. Subsidised Drug list. https:\/\/www.moh.gov.sg\/healthcare-schemes-subsidies\/subsidised-drug-list. Accessed 28 August 2023."},{"key":"ref15","unstructured":"American College of Rheumatology. Psoriatic Arthritis Guideline, 2018. https:\/\/rheumatology.org\/psoriatic-arthritis-guideline. Accessed 19 April 2024."},{"key":"ref16","unstructured":"Psoriasis: assessment and management. London: National Institute for Health and Care Excellence (NICE), 2017. (NICE Clinical Guidelines, No. 153). http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553610\/. Accessed 19 April 2024."},{"key":"ref17","unstructured":"Scottish Intercollegiate Guidelines Network. SIGN Grading System 1999\u20132012. https:\/\/www.sign.ac.uk\/assets\/sign_grading_system_1999_2012.pdf. Accessed 5 May 2022."},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Koh YP, Tian EA, Oon HH. New changes in pregnancy and lactation labelling: Review of dermatologic drugs. Int J Womens Dermatol 2019;5:216-26.","DOI":"10.1016\/j.ijwd.2019.05.002"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J Womens Dermatol 2019;5:141-50.","DOI":"10.1016\/j.ijwd.2019.04.021"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. J Am Acad Dermatol 2019;80:43-53.","DOI":"10.1016\/j.jaad.2018.06.056"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Puchner A, Gr\u00f6chenig HP, Sautner J, et al. Immunosuppressives and biologics during pregnancy and lactation: A consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation. Wien Klin Wochenschr 2019;131:29-44.","DOI":"10.1007\/s00508-019-1448-y"},{"key":"ref22","unstructured":"Food and Drug Administration. CLOBEX\u00ae (clobetasol propionate) Lotion, 0.05%, for topical use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021535Orig1s003,%20021644Orig1s003lbl.pdf. Accessed 4 April 2023."},{"key":"ref23","unstructured":"Food and Drug Administration. SORILUX (calcipotriene) foam, 0.005%, for topical use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022563s002lbl.pdf. Accessed 4 April 2023."},{"key":"ref24","unstructured":"Food and Drug Administration. ENSTILAR\u00ae (calcipotriene and betamethasone dipropionate) Foam, 0.005%\/0.064% for topical use. https:\/\/www.accessdata.fda.gov\/ drugsatfda_docs\/label\/2015\/207589s000lbl.pdf. Accessed 4 April 2023."},{"key":"ref25","unstructured":"Food and Drug Administration. OTEZLA\u00ae (apremilast) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/205437s011lbl.pdf. Accessed 4 April 2023."},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol 2014;70:401.e1-401.e14.","DOI":"10.1016\/j.jaad.2013.09.010"},{"key":"ref27","unstructured":"Food and Drug Administration. NEORAL\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050715s027,050716s028lbl.pdf. Accessed 4 April 2023."},{"key":"ref28","unstructured":"Food and Drug Administration. METHOTREXATE tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/040054s015,s016,s017.pdf. Accessed 4 April 2023."},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Government of Canada. Immunization of immunocompromised persons: Canadian Immunization Guide. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-3-vaccination-specific-populations\/page-8-immunization-immunocompromised-persons.html. Accessed 4 April 2023.","DOI":"10.14745\/ccdr.v42i12a04"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: care-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137-74.","DOI":"10.1016\/j.yder.2012.02.093"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Elewski BE, Puig L, Mordin M, et al. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75\u201389 response: results from two phase 3 studies of secukinumab. J Dermatol Treat 2017;28:492-99.","DOI":"10.1080\/09546634.2017.1307464"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther 2015;28:390-403.","DOI":"10.1111\/dth.12267"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol 2017;3:21-5.","DOI":"10.1016\/j.ijwd.2016.12.003"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Owczarek W, Walecka I, Lesiak A, et al. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. Postepy Dermatol Allergol 2020;37:821-30.","DOI":"10.5114\/ada.2020.102089"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Smith CH, Jabbar\u2010Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 2017;177:628-36.","DOI":"10.1111\/bjd.15665"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012;26:61-7.","DOI":"10.1111\/j.1468-3083.2012.04525.x"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007;57:81-3.","DOI":"10.1016\/j.jaad.2007.04.005"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Ibrahim GH, Buch MH, Lawson C, et al. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol 2009;27:469-74.","DOI":"10.1007\/s00296-016-3513-4"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Elmamoun M, Leung YY, O\u2019Sullivan D, et al. Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set. J Rheumatol 2019;46:266-73.","DOI":"10.3899\/jrheum.180195"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med 2017;376: 957-70.","DOI":"10.1056\/NEJMra1505557"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Generali E, Scir\u00e8 CA, Favalli EG, et al. Biomarkers in psoriatic arthritis: a systematic literature review. Expert Rev Clin Immunol 2016;12:651-60.","DOI":"10.1586\/1744666x.2016.1147954"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Eder L, Gladman DD. Predictors for clinical outcome in psoriatic arthritis \u2013 what have we learned from cohort studies? Expert Rev Clin Immunol 2014;10:763-70.","DOI":"10.1586\/1744666x.2014.905741"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020;79:700-12.","DOI":"10.1136\/annrheumdis-2020-218456"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Sakkas LI, Alexiou I, Simopoulou T, et al. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum 2013;43:325-34.","DOI":"10.1016\/j.semarthrit.2013.04.005"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Rose S, Toloza S, Bautista-Molano W, et al. Comprehensive Treatment of Dactylitis in Psoriatic Arthritis. J Rheumatol 2014;41:2295-300.","DOI":"10.3899\/jrheum.140879"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"G\u00f6testam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795-810.","DOI":"10.1136\/annrheumdis-2015-208840"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol 2020;82:161-201.","DOI":"10.1016\/j.jaad.2019.08.049"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52\u2010week results from a Phase 3 double\u2010blind randomized, controlled trial. J Eur Acad Dermatol Venereol 2021;35:938-47.","DOI":"10.1111\/jdv.17002"},{"key":"ref49","unstructured":"Food and Drug Administration. COSENTYX\u00ae (secukinumab) injection, for subcutaneous or intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761349s000lbl.pdf. Accessed 19 April 2024."},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Paller AS, Seyger MMB, Alejandro Magari\u00f1os G, et al. Efficacy and safety of ixekizumab in a phase III , randomized, double\u2010blind, placebo\u2010controlled study in paediatric patients with moderate\u2010to\u2010severe plaque psoriasis (IXORA \u2010 PEDS). Br J Dermatol 2020;183:231-41.","DOI":"10.1111\/bjd.19147"},{"key":"ref51","unstructured":"Food and Drug Administration. TALTZ (ixekizumab) injection, for subcutaneous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125521s020lbl.pdf. Accessed 19 April 2024."},{"key":"ref52","unstructured":"Food and Drug Administration. STELARA\u2122 (ustekinumab). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/125261lbl.pdf. Accessed 19 April 2024."},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Lansang P, Bergman JN, Fiorillo L, et al. Management of pediatric plaque psoriasis using biologics. J Am Acad Dermatol 2020;82:213-21.","DOI":"10.1016\/j.jaad.2019.05.056"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Grozdev IS, Van Voorhees AS, Gottlieb AB, et al. Psoriasis in the elderly: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2011;65: 537-45.","DOI":"10.1016\/j.jaad.2010.05.014"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Sandhu VK, Ighani A, Fleming P, et al. Biologic Treatment in Elderly Patients With Psoriasis: A Systematic Review. J Cutan Med Surg 2020;24:174-86.","DOI":"10.1177\/1203475419897578"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Nast A, Amelunxen L, Augustin M, et al. S3 Guideline for the treatment of psoriasis vulgaris, update \u2013 Short version part 2 \u2013 Special patient populations and treatment situations. J Dtsch Dermatol Ges 2018;16:806-13.","DOI":"10.1111\/ddg.13538"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Ang MLT, Chan SM, Cheng LT-E, et al. Singapore tuberculosis (TB) clinical management guidelines 2024: A modified Delphi adaptation of international guidelines for drug-susceptible TB infection and pulmonary disease. Ann Acad Med Singap 2024;53:170-86.","DOI":"10.47102\/https:\/\/doi.org\/10.47102\/annals-acadmedsg.2023391"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Plachouri K-M, Georgiou S. Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis. J Dermatolog Treat 2019;30:668-73.","DOI":"10.1080\/09546634.2018.1544413"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Megna M, Lauletta G, Tommasino N, et al. Management of Psoriasis Patients with Serious Infectious Diseases. Adv Ther 2024;41:2099-111.","DOI":"10.1007\/s12325-024-02873-2"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations. Am J Clin Dermatol 2019;20:829-45.","DOI":"10.1007\/s40257-019-00457-3"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Lau G, Yu M-L, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int 2021;15:1031-48.","DOI":"10.1007\/s12072-021-10239-x"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015;148:215-9.","DOI":"10.1053\/j.gastro.2014.10.039"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Martinello M, Naggie S, Rockstroh JK, et al. Direct-acting antiviral therapy for treatment of acute and recent hepatitis C virus infection: a narrative review. Clin Infect Dis 2023;77:S238-44.","DOI":"10.1093\/cid\/ciad344"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Plachouri KM, Georgiou S. Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis. Int J Dermatol 2019;58:1008-13.","DOI":"10.1111\/ijd.14436"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol 2019;81:775-804.","DOI":"10.1016\/j.jaad.2019.04.042"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Takeshita J, Shin DB, Ogdie A, et al. Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom. J Invest Dermatol 2018;138:1726-35.","DOI":"10.1016\/j.jid.2018.01.039"},{"key":"ref67","unstructured":"The National Psoriasis Foundation. Report Vaccinating While On Biologics Requires Special Care. https:\/\/www.psoriasis.org\/media\/press-releases\/report-vaccinating-while-biologics-requires-special-care. Accessed 2 December 2022."}],"container-title":["Annals of the Academy of Medicine, Singapore"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T02:37:44Z","timestamp":1727404664000},"score":1,"resource":{"primary":{"URL":"https:\/\/annals.edu.sg\/2023-guidelines-on-the-management-of-psoriasis-by-the-dermatological-society-of-singapore\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":68,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,27]]},"published-print":{"date-parts":[[2024,9,27]]}},"URL":"https:\/\/doi.org\/10.47102\/annals-acadmedsg.2023367","relation":{},"ISSN":["0304-4602"],"issn-type":[{"value":"0304-4602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}